Sensitive and quantitative monitoring of BCR-ABL mRNA in patients with chronic myelogenous leukemia (CML)
New Ways. New Innovations. New Paths Towards Disease Management.
Cancer is Hard. Testing for it Shouldn’t Be.
Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focus on cancers of the breast, bladder, and blood. Harnessing the power of quantitative PCR technology and the world’s most popular molecular diagnostics platform1, Cepheid oncology products provide on-site, on-demand, standardized, and reliable results.
Cepheid expanded its breast cancer diagnostics capabilities with the acquisition of OncoMark, a company that developed technology to estimate the likelihood of early-stage breast cancer recurrence after treatment. Optimized to run on the Cepheid GeneXpert® systems, the technology uses a proprietary algorithm to produce a binary risk score (high risk vs low risk) to predict the likelihood of disease recurrence in the next 10 years.
Cepheid also continues to offer the Xpert® Breast Cancer STRAT4 biomarker test in countries accepting the CE-IVD mark.
To learn more, contact the Cepheid Medical and Scientific Affairs and Strategy team for Oncology at: MedSci.Oncology@Cepheid.com.
Xpert Breast Cancer STRAT-4 is not available in the US.
With Cepheid’s proven “lab in a cartridge,” our tests give patients and their doctors peace of mind when it matters most. The pioneering mindset of our oncology team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor.
Detection of the presence of bladder cancer in patients with hematuria in 90 minutes
Qualitative monitoring for recurrence in patients previously diagnosed with bladder cancer in 90 minutes
CE IVD and US-IVD. In Vitro Diagnostic Medical Device. Not available in all counties.
CE IVD. In Vitro Diagnostic Medical Device. Not available in all counties. Not available in the United States.
Discover a Better Path with Xpert BCR-ABL Ultra2
The high sensitivity of the Cepheid BCR-ABL test, Xpert BCR-ABL Ultra*, allows for monitoring of disease even at low levels, thereby providing an essential aid for clinicians to manage their patients with CML, using IS-standardized molecular testing
Xpert® BCR-ABL Ultra Resources:
Xpert® Bladder Cancer Detection3 & Xpert® Bladder Cancer Monitor3
Xpert Bladder Cancer Detection and Xpert Bladder Cancer Monitor* are two easy to use, non-invasive bladder cancer tests. Xpert Bladder Cancer Detection* is intended to detect the presence of bladder cancer in patients with hematuria. Xpert Bladder Cancer Monitor* is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer. Both tests measure five bladder cancer- specific biomarkers and require only a urine sample from the patient.
Visit the Xpert Bladder Cancer Monitor Product Page
Xpert Bladder Cancer Detection & Monitor Resources:
Xpert Breast Cancer STRAT4
Xpert Breast Cancer STRAT4* is an mRNA-based test that standardizes and simplifies the assessment of ESR1, PGR, ERBB2, and MKi67 breast cancer biomarkers. In less than 2 hours, the test provides objective and reproducible results that are well-correlated with central lab IHC/ISH methods. Clear and accurate results empower pathologists and oncologists.
Xpert Breast Cancer STRAT4* Resources
Xpert Breast Cancer STRAT4 Product Brochure
Standardized breast cancer ESR1, PGR, ERBB2, and MKi67 mRNA biomarker assessment in less than two hours
Xpert Breast Cancer STRAT4 Educational Brochure
A faster and more objective solution compared to traditional breast cancer biomarker testing methods.
Xpert FII & FV Product Brochure
30 Minute Test for Genetic Risk of Thrombosis Xpert® FII & FV is a qualitative genotyping test for the rapid detection of Factor II (FII) and Factor V (FV) alleles. Performed on the Cepheid GeneXpert System, the test is intended to provide rapid results for FII (G20210A) and FV Leiden (G1691A) mutations as an aid in the diagnosis of suspected thrombophilia.
Journey Inside the Cepheid GeneXpert® Cartridge
Prior to Cepheid, the industry was set on two things: batch testing and the idea of a simple test disposable running on a large, complex system. Cepheid changed all that with the first random access system – enabling tests to be run ‘on-demand’ instead of in large batches. Cepheid further improved accessibility by taking much of the complexity out of the system and putting it into a patented, self-contained, single use cartridge. Sample extraction, amplification and detection are all carried out within this ‘laboratory in a cartridge’. Take a tour inside this amazing technology:
Meet our Game-Changing Platform
With over 20,000 installed systems worldwide, the GeneXpert System is the molecular testing platform of choice for most laboratory specialists. See how it’s helping clinicians everywhere make a more positive impact.
1. Based on July 2019 market research conducted by Kalorama Information with sample respondents in select countries.
2. CE IVD and US-IVD. In Vitro Diagnostic Medical Device. Not available in all counties.
3. CE IVD. In Vitro Diagnostic Medical Device. Not available in all counties. Not available in the United States.